- Home
- ALLK vs NXTC Comparison
ALLK vs NXTC Comparison
Compare ALLK & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- NXTC
- Stock Information
- Founded
- ALLK 2012
- NXTC 2015
- Country
- ALLK United States
- NXTC United States
- Employees
- ALLK N/A
- NXTC N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- ALLK Health Care
- NXTC Health Care
- Exchange
- ALLK Nasdaq
- NXTC Nasdaq
- Market Cap
- ALLK 23.0M
- NXTC 20.6M
- IPO Year
- ALLK 2018
- NXTC 2019
- Fundamental
- Price
- ALLK $0.32
- NXTC $0.40
- Analyst Decision
- ALLK Hold
- NXTC Strong Buy
- Analyst Count
- ALLK 3
- NXTC 2
- Target Price
- ALLK $2.00
- NXTC $3.50
- AVG Volume (30 Days)
- ALLK 1.8M
- NXTC 99.1K
- Earning Date
- ALLK 03-12-2025
- NXTC 03-06-2025
- Dividend Yield
- ALLK N/A
- NXTC N/A
- EPS Growth
- ALLK N/A
- NXTC N/A
- EPS
- ALLK N/A
- NXTC N/A
- Revenue
- ALLK N/A
- NXTC N/A
- Revenue This Year
- ALLK N/A
- NXTC N/A
- Revenue Next Year
- ALLK N/A
- NXTC N/A
- P/E Ratio
- ALLK N/A
- NXTC N/A
- Revenue Growth
- ALLK N/A
- NXTC N/A
- 52 Week Low
- ALLK $0.22
- NXTC $0.35
- 52 Week High
- ALLK $1.56
- NXTC $2.49
- Technical
- Relative Strength Index (RSI)
- ALLK 59.90
- NXTC 22.20
- Support Level
- ALLK $0.24
- NXTC $0.49
- Resistance Level
- ALLK $0.27
- NXTC $0.67
- Average True Range (ATR)
- ALLK 0.01
- NXTC 0.09
- MACD
- ALLK 0.01
- NXTC -0.02
- Stochastic Oscillator
- ALLK 96.94
- NXTC 12.74
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.